Indeed, 50% of patients do not adequately respond to anti-PD-L1/anti-PD-1 monotherapy (treatment resistant, or relapsed) and second-line therapy in MCC is still uncoded. The gene discussed is PDCD1; the disease is Merkel cell skin cancer.